Silence Therapeutics Shareholders Approve All AGM Resolutions
Ticker: SLNCF · Form: 6-K · Filed: May 17, 2024 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 6-K |
| Filed Date | May 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agm, shareholder-meeting, corporate-governance
TL;DR
Silence Therapeutics AGM: All shareholder votes passed, company moves forward.
AI Summary
Silence Therapeutics plc announced on May 17, 2024, that all resolutions presented at its Annual General Meeting were approved by shareholders. The company is incorporated in the United Kingdom and its principal executive offices are located at 72 Hammersmith Road, London.
Why It Matters
Shareholder approval of all resolutions at the Annual General Meeting indicates confidence from investors and allows the company to proceed with its planned corporate actions.
Risk Assessment
Risk Level: low — This filing is a routine announcement of the results of an Annual General Meeting and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- May 17, 2024 (date) — Date of Annual General Meeting
- 72 Hammersmith Road, London W14 8TH, United Kingdom (location) — Principal executive offices
FAQ
What was the purpose of the Form 6-K filing?
The Form 6-K filing was made to announce that all resolutions presented at Silence Therapeutics plc's Annual General Meeting held on May 17, 2024, were duly passed by the Company's shareholders.
When was the Annual General Meeting of Silence Therapeutics plc held?
The Annual General Meeting of Silence Therapeutics plc was held on May 17, 2024.
Were all resolutions proposed at the AGM approved?
Yes, the filing states that all resolutions set forth in the Company's Notice of Annual General Meeting were duly passed by the Company's shareholders.
What is the principal executive office address for Silence Therapeutics plc?
The principal executive offices of Silence Therapeutics plc are located at 72 Hammersmith Road, London W14 8TH, United Kingdom.
Does Silence Therapeutics plc file annual reports under Form 20-F?
Yes, the filing indicates by check mark that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 223 words · 1 min read · ~1 pages · Grade level 18.4 · Accepted 2024-05-17 17:04:57
Filing Documents
- d832504d6k.htm (6-K) — 8KB
- 0001193125-24-141853.txt ( ) — 9KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Silence Therapeutics plc (the Company) today announces that at its Annual General Meeting held on May 17, 2024, all resolutions set forth in the Companys Notice of Annual General Meeting were duly passed by the Companys shareholders by way of poll. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Silence Therapeutics plc By: /s/ Craig Tooman Name: Craig Tooman Title: President and Chief Executive Officer Date: May 17, 2024